US EditionVC firm Vivo Capital outlays $740m for biotech investment - Pharmaceutical Technology
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Vivo Capital closes $740m public fund - Private Equity Wire
Vivo Capital, a global investment firm focused exclusively on healthcare and life sciences, has closed the third cycle of its Vivo Opportunity Fund and its affiliates with over $740m in commitments. The Public Fund invests in preclinical and clinical stage life sciences businesses that are developing or commercialising novel therapies for unmet medical needs. Vivo Opportunity Fund is an evergreen fund with three-year investment cycles. The third…
Vivo Capital looks to capture value from medical breakthroughs with $740m boost to evergreen fund
Sino-US healthcare investment specialist Vivo Capital has scored more than $740m for the third cycle of its evergreen Opportunity Fund, which targets small and mid-cap biotech and life science companies. The post Vivo Capital looks to capture value from medical breakthroughs with $740m boost to evergreen fund appeared first on AltAssets Private Equity News.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage